Trade Kala Pharma - KALA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.23 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 7.81 |
Open* | 7.6 |
1-Year Change* | -48.92% |
Day's Range* | 7.6 - 7.85 |
52 wk Range | 0.17-2.29 |
Average Volume (10 days) | 1.21M |
Average Volume (3 months) | 23.44M |
Market Cap | 14.64M |
P/E Ratio | -100.00K |
Shares Outstanding | 73.21M |
Revenue | 8.40M |
EPS | -1.95 |
Dividend (Yield %) | N/A |
Beta | 1.14 |
Next Earnings Date | Nov 14, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 7.81 | 0.17 | 2.23% | 7.64 | 7.89 | 7.64 |
Mar 26, 2024 | 7.83 | 0.12 | 1.56% | 7.71 | 7.87 | 7.58 |
Mar 25, 2024 | 7.86 | 0.02 | 0.26% | 7.84 | 7.93 | 7.84 |
Mar 22, 2024 | 7.87 | 0.04 | 0.51% | 7.83 | 7.87 | 7.77 |
Mar 21, 2024 | 7.81 | 0.23 | 3.03% | 7.58 | 7.94 | 7.58 |
Mar 20, 2024 | 7.76 | 0.10 | 1.31% | 7.66 | 7.92 | 7.66 |
Mar 19, 2024 | 7.66 | 0.15 | 2.00% | 7.51 | 7.67 | 7.51 |
Mar 18, 2024 | 7.66 | 0.19 | 2.54% | 7.47 | 7.86 | 7.47 |
Mar 15, 2024 | 7.51 | 0.04 | 0.54% | 7.47 | 7.64 | 7.47 |
Mar 14, 2024 | 7.48 | -0.01 | -0.13% | 7.49 | 7.56 | 7.34 |
Mar 13, 2024 | 7.50 | 0.04 | 0.54% | 7.46 | 7.61 | 7.38 |
Mar 12, 2024 | 7.53 | 0.06 | 0.80% | 7.47 | 7.60 | 7.47 |
Mar 11, 2024 | 7.51 | 0.07 | 0.94% | 7.44 | 7.78 | 7.39 |
Mar 8, 2024 | 7.36 | 0.10 | 1.38% | 7.26 | 7.47 | 7.26 |
Mar 7, 2024 | 7.28 | -0.03 | -0.41% | 7.31 | 7.46 | 7.26 |
Mar 6, 2024 | 7.33 | -0.03 | -0.41% | 7.36 | 7.46 | 7.26 |
Mar 5, 2024 | 7.37 | 0.11 | 1.52% | 7.26 | 7.48 | 7.26 |
Mar 4, 2024 | 7.49 | 0.22 | 3.03% | 7.27 | 7.71 | 7.26 |
Mar 1, 2024 | 7.27 | 0.25 | 3.56% | 7.02 | 7.36 | 6.99 |
Feb 29, 2024 | 7.05 | -0.09 | -1.26% | 7.14 | 7.16 | 6.97 |
Kala Pharma Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 11.24 | 6.362 | 6.074 | 0 | 0 |
Revenue | 11.24 | 6.362 | 6.074 | 0 | 0 |
Total Operating Expense | 145.569 | 102.593 | 94.298 | 65.111 | 39.875 |
Selling/General/Admin. Expenses, Total | 105.061 | 81.068 | 65.015 | 35.431 | 10.867 |
Research & Development | 38.132 | 18.352 | 27.275 | 29.29 | 29.008 |
Operating Income | -134.329 | -96.231 | -88.224 | -65.111 | -39.875 |
Interest Income (Expense), Net Non-Operating | -8.276 | -8.096 | -6.123 | -1.627 | -2.336 |
Net Income Before Taxes | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
Net Income After Taxes | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
Net Income Before Extra. Items | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
Net Income | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
Income Available to Common Excl. Extra. Items | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
Income Available to Common Incl. Extra. Items | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
Dilution Adjustment | |||||
Diluted Net Income | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
Diluted Weighted Average Shares | 65.2028 | 52.3775 | 34.2098 | 26.7539 | 6.90324 |
Diluted EPS Excluding Extraordinary Items | -2.1871 | -1.99183 | -2.7579 | -2.49451 | -6.11467 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Diluted Normalized EPS | -2.12446 | -1.99183 | -2.7579 | -2.47994 | -6.11467 |
Unusual Expense (Income) | 4.084 | 0 | 0.39 | ||
Cost of Revenue, Total | 4.097 | 3.173 | 2.008 | ||
Gross Profit | 7.143 | 3.189 | 4.066 | ||
Other Operating Expenses, Total | -5.805 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 1.372 | 1.856 | 3.067 | 3.051 | 3.266 |
Revenue | 1.372 | 1.856 | 3.067 | 3.051 | 3.266 |
Cost of Revenue, Total | 0.775 | 1.418 | 0.908 | 1.016 | 0.755 |
Gross Profit | 0.597 | 0.438 | 2.159 | 2.035 | 2.511 |
Total Operating Expense | 32.286 | 47.36 | 29.138 | 37.491 | 31.58 |
Selling/General/Admin. Expenses, Total | 26.982 | 24.027 | 25.349 | 27.986 | 27.699 |
Research & Development | 4.466 | 29.031 | 2.881 | 3.094 | 3.126 |
Operating Income | -30.914 | -45.504 | -26.071 | -34.44 | -28.314 |
Interest Income (Expense), Net Non-Operating | -2.027 | -2.064 | -2.056 | -2.058 | -2.098 |
Net Income Before Taxes | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
Net Income After Taxes | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
Net Income Before Extra. Items | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
Net Income | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
Income Available to Common Excl. Extra. Items | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
Income Available to Common Incl. Extra. Items | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
Diluted Net Income | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
Diluted Weighted Average Shares | 73.6408 | 69.5132 | 65.0505 | 64.5545 | 61.6559 |
Diluted EPS Excluding Extraordinary Items | -0.44732 | -0.6843 | -0.43239 | -0.56538 | -0.49325 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.44732 | -0.70316 | -0.43239 | -0.48181 | -0.49325 |
Unusual Expense (Income) | -1.311 | 0 | 5.395 | ||
Other Operating Expenses, Total | 0.063 | -5.805 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 124.366 | 171.379 | 105.484 | 177.028 | 115.213 |
Cash and Short Term Investments | 92.136 | 153.54 | 85.449 | 170.898 | 114.565 |
Cash | 92.136 | 77.264 | 85.449 | 170.898 | 114.565 |
Prepaid Expenses | 1.307 | 1.807 | 1.605 | 0.532 | 0.648 |
Other Current Assets, Total | 4.829 | 0.949 | 0.684 | 0.477 | |
Total Assets | 139.427 | 221.606 | 154.323 | 220.966 | 116.546 |
Property/Plant/Equipment, Total - Net | 4.021 | 31.019 | 32.479 | 31.732 | 1.199 |
Property/Plant/Equipment, Total - Gross | 6.882 | 34.443 | 34.995 | 33.55 | |
Accumulated Depreciation, Total | -2.861 | -3.424 | -2.516 | -1.818 | |
Other Long Term Assets, Total | 11.04 | 19.208 | 16.36 | 12.206 | 0.134 |
Total Current Liabilities | 37.422 | 22.225 | 24.774 | 17.01 | 14.872 |
Accounts Payable | 4.899 | 1.724 | 2.518 | 5.446 | 1.202 |
Accrued Expenses | 21.697 | 20.501 | 22.256 | 11.564 | 7.003 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 6.667 | |||
Total Liabilities | 122.623 | 121.611 | 124.631 | 115.988 | 26.867 |
Total Long Term Debt | 78.929 | 72.243 | 71.184 | 70.226 | 11.987 |
Long Term Debt | 78.929 | 72.243 | 71.184 | 70.226 | 11.987 |
Other Liabilities, Total | 6.272 | 27.143 | 28.673 | 28.752 | 0.008 |
Total Equity | 16.804 | 99.995 | 29.692 | 104.978 | 89.679 |
Redeemable Preferred Stock | 0 | 0 | |||
Common Stock | 0.066 | 0.059 | 0.036 | 0.034 | 0.025 |
Additional Paid-In Capital | 559.126 | 499.715 | 325.112 | 306.053 | 224.025 |
Retained Earnings (Accumulated Deficit) | -542.388 | -399.783 | -295.456 | -201.109 | -134.371 |
Total Liabilities & Shareholders’ Equity | 139.427 | 221.606 | 154.323 | 220.966 | 116.546 |
Total Common Shares Outstanding | 65.5003 | 58.9154 | 36.0863 | 33.8631 | 24.5383 |
Total Receivables, Net | 17.455 | 9.854 | 13.098 | 1.026 | |
Total Inventory | 8.639 | 5.229 | 4.648 | 4.095 | |
Accounts Receivable - Trade, Net | 15.345 | 9.604 | 11.563 | ||
Short Term Investments | 0 | 76.276 | |||
Other Equity, Total | 0 | 0.004 | |||
Other Current Liabilities, Total | 10.826 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 98.255 | 124.366 | 149.086 | 171.72 | 179.065 |
Cash and Short Term Investments | 70.162 | 92.136 | 124.503 | 149.635 | 155.985 |
Cash | 65.17 | 92.136 | 124.503 | 144.635 | 127.97 |
Short Term Investments | 4.992 | 0 | 0 | 5 | 28.015 |
Total Receivables, Net | 13.02 | 15.345 | 12.63 | 11.859 | 12.206 |
Accounts Receivable - Trade, Net | 13.02 | 15.345 | 12.63 | 11.859 | 12.206 |
Total Inventory | 10.531 | 8.639 | 7.708 | 8.046 | 8.241 |
Prepaid Expenses | 4.542 | 5.293 | 4.245 | 2.18 | 2.633 |
Total Assets | 111.574 | 139.427 | 193.814 | 215.464 | 229.827 |
Property/Plant/Equipment, Total - Net | 4.089 | 4.021 | 30.481 | 31.369 | 31.584 |
Other Long Term Assets, Total | 9.23 | 11.04 | 14.247 | 12.375 | 19.178 |
Total Current Liabilities | 32.758 | 37.422 | 27.195 | 26.076 | 19.989 |
Accounts Payable | 6.218 | 4.899 | 5.845 | 2.844 | 2.855 |
Accrued Expenses | 21.864 | 21.697 | 21.35 | 23.232 | 17.134 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 116.858 | 122.623 | 132.345 | 131.194 | 120.035 |
Total Long Term Debt | 79.361 | 78.929 | 78.491 | 78.055 | 72.521 |
Long Term Debt | 79.361 | 78.929 | 78.491 | 78.055 | 72.521 |
Other Liabilities, Total | 4.739 | 6.272 | 26.659 | 27.063 | 27.525 |
Total Equity | -5.284 | 16.804 | 61.469 | 84.27 | 109.792 |
Common Stock | 0.073 | 0.066 | 0.065 | 0.065 | 0.064 |
Additional Paid-In Capital | 569.974 | 559.126 | 556.224 | 550.898 | 539.92 |
Retained Earnings (Accumulated Deficit) | -575.329 | -542.388 | -494.82 | -466.693 | -430.195 |
Other Equity, Total | -0.002 | 0 | 0 | 0 | 0.003 |
Total Liabilities & Shareholders’ Equity | 111.574 | 139.427 | 193.814 | 215.464 | 229.827 |
Total Common Shares Outstanding | 72.594 | 65.5003 | 65.0852 | 64.7702 | 63.8051 |
Other Current Assets, Total | 2.953 | ||||
Accumulated Depreciation, Total | -2.861 | ||||
Other Current Liabilities, Total | 4.676 | 10.826 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
Cash From Operating Activities | -108.235 | -90.694 | -92.72 | -54.121 | -34.098 |
Cash From Operating Activities | 0.975 | 0.912 | 0.843 | 0.352 | 0.287 |
Non-Cash Items | 44.011 | 16.294 | 12.722 | 9.882 | 5.526 |
Cash Interest Paid | 6.837 | 7.528 | 7.522 | 3.041 | 0.863 |
Changes in Working Capital | -10.616 | -3.573 | -11.938 | 2.383 | 2.3 |
Cash From Investing Activities | 70.803 | -78.209 | -1.335 | -1.578 | -0.48 |
Capital Expenditures | -0.886 | -1.942 | -1.335 | -1.578 | -0.48 |
Cash From Financing Activities | 42.554 | 160.628 | 8.982 | 124.104 | 103.696 |
Financing Cash Flow Items | -2.25 | ||||
Issuance (Retirement) of Stock, Net | 42.817 | 160.66 | 9.012 | 71.296 | 97.057 |
Issuance (Retirement) of Debt, Net | -0.263 | -0.032 | -0.03 | 52.808 | 8.889 |
Net Change in Cash | 5.122 | -8.275 | -85.073 | 68.405 | 69.118 |
Other Investing Cash Flow Items, Total | 71.689 | -76.267 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -32.941 | -142.605 | -95.037 | -66.91 | -30.412 |
Cash From Operating Activities | -24.089 | -108.235 | -80.331 | -54.248 | -32.64 |
Cash From Operating Activities | 0.157 | 0.975 | 0.763 | 0.504 | 0.248 |
Non-Cash Items | 3.479 | 44.011 | 21.534 | 16.592 | 5.519 |
Cash Interest Paid | 1.603 | 6.837 | 5.2 | 3.03 | 1.851 |
Changes in Working Capital | 5.216 | -10.616 | -7.591 | -4.434 | -7.995 |
Cash From Investing Activities | -5.073 | 70.803 | 75.426 | 70.705 | 48.031 |
Capital Expenditures | -0.081 | -0.886 | -0.874 | -0.545 | -0.219 |
Other Investing Cash Flow Items, Total | -4.992 | 71.689 | 76.3 | 71.25 | 48.25 |
Cash From Financing Activities | 0.154 | 42.554 | 42.394 | 41.164 | 35.315 |
Issuance (Retirement) of Stock, Net | 0.163 | 42.817 | 42.648 | 41.409 | 35.324 |
Issuance (Retirement) of Debt, Net | -0.009 | -0.263 | -0.254 | -0.245 | -0.009 |
Net Change in Cash | -29.008 | 5.122 | 37.489 | 57.621 | 50.706 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Kala Pharma Company profile
About Kala Pharmaceuticals Inc
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for diseases of the eye. The Company's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The Company's AMPPLIFY technology uses selectively-sized nanoparticles that each have a proprietary coating. Its Preclinical Development Programs include rTKI Program for Retinal Diseases (KPI-285/KPI-286), SEGRM Program and Surface Targeted Steroid Program (KPI-333).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Kala Pharmaceuticals Inc revenues increased from $4.1M to $9.4M. Net loss increased 30% to $95M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 48% to $70.6M (expense), Stock-Based Compensation increase of 50% to $10.4M (expense).
Industry: | Pharmaceuticals (NEC) |
1167 Massachusetts Avenue
02476
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com